Epsilogen names Cristina Oliva as CMO

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, today announced the appointment of Cristina Oliva as chief medical officer (CMO). Dr Oliva is a board-certified oncologist and brings global experience across all stages of oncology drug development.

Dr Oliva joins Epsilogen from BerGenBio, where she served as CMO from 2022. Prior to this role, Dr Oliva was vice president, oncology and head of Oncology Centre of Excellence at IQVIA, where she led a cross-functional team of oncology subject matter experts and established and led the IQVIA oncology global scientific advisory board. Dr Oliva has also held senior positions, leading oncology development programs, at Nordic Nanovector, Takeda (TYO: 4502), GSK (LSE: GSK) and Eli Lilly (NYSE: LLY).

Tim Wilson, chief executive of Epsilogen, said: “I am delighted to welcome Cristina to Epsilogen. I believe her extensive experience in oncology drug development will be invaluable as we continue to advance MOv18 IgE through Phase Ib studies and progress other assets from our unique IgE, IgA and IgG-based therapeutics platforms towards the clinic.”